Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination
CompanyDrug

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Eli Lilly and Company (NYSE: LLY) announced new first‑line data on olomorasib, its investigational next‑generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid,…

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

SCIEX Breaks Ground on Beijing Mass Spectrometry Manufacturing Site – Danaher's 10th Production Facility in China, Making Beijing Its First City Globally with Three Manufacturing Sites

SCIEX Breaks Ground on Beijing Mass Spectrometry Manufacturing Site – Danaher’s 10th Production Facility in China, Making Beijing Its First City Globally with Three Manufacturing Sites

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy
CompanyDrug

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
CompanyDrug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
CompanyDeals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

HutchMed's Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
CompanyDrug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
CompanyDrug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

CompanyDrug

Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer

CompanyDrug

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Show More